複雑性尿路感染症に対するTosufloxacinの再発予防効果

Abstract

複雑性尿路感染症に初期治療としてTFLX 150mgを1日3回7～14日投与した。その後TFLX 150mg就寝前1回投与を行い4～12週後再発予防効果を検討した。1)初期治療の検討:UTI薬効評価基準に従い評価可能であった45例の総合臨床効果は, 著効31例, 有効8例, 無効6例であった。2)再発予防の検討を行った39例中再発を認めたのは3例であった。3)初期治療, 再発予防検討中TFLXに起因すると思われる副作用はなかった

Forty five patients with complicated urinary tract infections were treated with tosufloxacin (TFLX) in the initial antibacterial treatment. Excellent and moderate responses were obtained in 39 patients (86.7%). No side effects were seen. Clinical efficacy and safety of long-term preventive administration of TFLX (150mg, a day) were also examined in 39 patients who showed an excellent or a moderate response in the initial treatment. The period of the administration ranged from 28 to 112 days (average; 55 days). The rate of preventing recurrence of urinary tract infection was 92.3% on the last day of treatment. These findings suggested that TFLX was useful not only in treating the patients with complicated urinary tract infections but also in preventing recurrence of urinary tract infection.